Molecular characterization of early breast cancer onset to understand disease phenotypes in African patients.

Pamela Derliche Tonouo, Esther Dina Bell, Arnol Auvaker Tiofack Zebaze, Eliane Ndounga, Sidonie Noa Ananga, Etienne Atenguena, Gustave Simo, Abdel Jelil Njouendou, Smiths S Lueong

Journal: Medical oncology (Northwood, London, England) 2022;40(1):13

PMID: 36352274

Abstract

Female breast cancer (BC) is the leading cause of cancer-related deaths worldwide with higher mortality rates and early onset in developing countries. The molecular basis of early disease onset is still elusive. We recruited 472 female breast cancer from two sub-Saharan African countries (Cameroon and Congo) between 2007 and 2018 and collected clinical data from these patients. To investigate the molecular drivers of early disease onset, we analyzed publicly available breast cancer molecular data from the cancer genome atlas (TCGA) and the gene expression omnibus (GEO) for copy number alteration, mutation and gene expression. Early BC onset (EOBRCA) (diagnosis before 45 years) was higher in African women compared with the TCGA cohort (51.7% vs 15.6%). The tumor grade, mitotic index, HER2 + phenotype, basal-like phenotype and ki67 were higher in EOBRCA for all cohorts. BC risk factors such as parity, breastfeeding early onset of menarche and use of hormonal contraceptives were significantly associated with EOBRCA (p < 0.05). EOBRCA was equally associated with copy number alterations in several oncogenes including CDH6 and FOXM1 and tumor suppressor including TGM3 and DMBT1 as well as higher TP53 mutation rates (OR: 2.93, p < 0.01). There was a significant enrichment of TGFß signaling in EOBRCA with TGM3 deletions, which was associated with high expression of all SMAD transcription factors as well as WNT ligands. The Frizzled receptors FZD1, FZD4 and FZD6 were significantly upregulated in EOBRCA, suggesting activation of non-canonical WNT signaling. Our data, suggest the implication of TGM3 deletion in early breast cancer onset. Further molecular investigations are warranted in African patients.

© 2022. The Author(s).

Address: Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon.; Department of Medical Oncology Douala General Hospital, Douala, Cameroon.; Molecular Parasitology and Entomology Unit (MPEU), Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon.; Centre Hospitalier Universitaire de Brazzaville, Brazzaville, Congo.; Department of Medical Oncology, Yaoundé General Hospital Cameroon and the Cameroon Cancer Registry, Yaoundé, Cameroon.; Department of Biomedical Sciences, Faculty of Health Sciences, University of Buea, Buea, Cameroon.; Molecular Parasitology and Entomology Unit (MPEU), Department of Biochemistry, Faculty of Science, University of Dschang, Dschang, Cameroon. [email protected].; Bridge Institute for Experimental Cancer Therapy, West German Cancer Center, University Hospital Essen, Hufeland Str. 55, 45147, Essen, Germany. [email protected].; Division for Solid Tumor Translational Oncology, The German Consortium for Translational Cancer Research (DKTK) and the German Cancer Research Center (DKFZ), Essen/Düsseldorf Partner Site, West German Cancer Center, University Hospital Essen, Essen, Germany. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.